Corium, Inc. Announces FDA Filing Acceptance Of New Drug Application For ADLARITY® For The Treatment Of Alzheimer’s Disease

Corium, Inc., a commercial-stage biopharmaceutical company for the development of novel transdermal health care products that are intended to provide alternative treatment options for consumers and their families, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for ADLARITY (donepezil transdermal system), its lead investigational agent for the treatment of dementia of the Alzheimer’s type in individuals with mild, moderate, and severe Alzheimer’s disease. The FDA has set a Prescription Drug User Fee Act target action date of July 30, 2020.

ADLARITY (donepezil transdermal system . . .